Journal of Alzheimers Disease & Parkinsonism
天美传媒 Access
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 天美传媒 Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
天美传媒 Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 4334
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- 天美传媒 J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- China National Knowledge Infrastructure (CNKI)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
A new direction for Alzheimer′s research
10th International Conference on Vascular Dementia
James D Weinstein
Marshall University, USA
ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism
DOI:
Abstract
Although billions of dollars have been spent for research on Alzheimer芒�?�?s disease (AD), little progress has been made in finding a therapy which stops the progressive dementia characteristic of the disease. Numerous drugs, having failed over years of research suggests the need for re-evaluation of how the research is now being done. To that end, three changes in current AD research methodology are offered and these changes are absolutely necessary to provide the means to find an effective treatment for the disease. First, AD is a disease of four etiologies rather than from a single primary cause. These four should be treated simultaneously for an effective therapy. Second, AD drug testing is wasting much time effort and money by aiming for a statistical verification of the slowing of dementia. The end point should be the complete cessation of progressive dementia, and testing should begin with small cohorts. Third, combination therapies with drugs currently available, used off label, ought to be tried. One example of such a combination is reviewed.Biography
James D Weinstein has completed his MD in 1964 from University of Pennsylvania and his Internship from New England Center Hospital in Boston in 1965. He has worked as a Neurosurgeon for more than 40 years in New Jersey and West Virginia. He has published more than 25 papers in reputed journals.
Email:jweinstein3438@gmail.com
